title: Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development.
abstract: Myeloproliferative neoplasms (essential thrombocythemia, ET; polycythemia vera, PV; myelofibrosis, MF) are monoclonal malignancies associated with genomic instability, dysregulated signaling pathways, and subsequent overproduction of inflammatory markers. Acknowledged for their debilitating symptom profiles, recent investigations have aimed to determine the identity of these markers, the upstream sources stimulating their development, their prevalence within the MPN population, and the role they play in symptom development. Creation of dedicated Patient Reported Outcome (PRO) tools, in combination with expanded access to cytokine analysis technology, has resulted in a surge of investigations evaluating the potential associations between symptoms and inflammation. Emerging data demonstrates clear relationships between individual MPN symptoms (fatigue, abdominal complaints, microvascular symptoms, and constitutional symptoms) and cytokines, particularly IL-1, IL-6, IL-8, and TNF-α. Information is also compiling on the role symptoms paradoxically play in the development of cytokines, as in the case of fatigue-driven sedentary lifestyles. In this paper, we explore the symptoms inherent to the MPN disorders and the potential role inflammation plays in their development.
authors.affiliation: Division of Hospital Internal Medicine, Mayo Clinic, Scottsdale, AZ 85054, USA.
authors.forename: Holly L
authors.initials: HL
authors.lastname: Geyer
authors.affiliation: Department of Statistics, Mayo Clinic, Scottsdale, AZ 85054, USA.
authors.forename: Amylou C
authors.initials: AC
authors.lastname: Dueck
authors.affiliation: Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ 85054, USA.
authors.forename: Robyn M
authors.initials: RM
authors.lastname: Scherber
authors.affiliation: Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ 85054, USA.
authors.forename: Ruben A
authors.initials: RA
authors.lastname: Mesa
mesh_terms: D000818:Animals; D003072:Cognition Disorders / Q000150:complications; D016207:Cytokines / Q000378:metabolism; D018450:Disease Progression; D005221:Fatigue; D006801:Humans; D007249:Inflammation / Q000473:pathology*; D008833:Microcirculation; D009196:Myeloproliferative Disorders / Q000473:pathology*; D011087:Polycythemia Vera / Q000473:pathology*; D055728:Primary Myelofibrosis / Q000473:pathology*; D011537:Pruritus / Q000150:complications; D013163:Splenomegaly; D063189:Symptom Assessment; D013920:Thrombocythemia, Essential / Q000473:pathology*; D016896:Treatment Outcome
chemical_list: D016207:Cytokines